Skip to content

Clinical trials

Phase 1/2 Leukemia, B-Cell trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, B-Cell Phase: Phase 1/2 Clear all

33 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20102
20111
20121
20141
20163
20174
20182
20193
20202
20212
20222
20231
20243
20253
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status11
Completed7
Recruiting6
Active, not recruiting3
Terminated2
Not yet recruiting2
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chongqing Precision Biotech Co., Ltd4
AstraZeneca2
Chinese PLA General Hospital2
Shenzhen Geno-Immune Medical Institute2
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China1
AVM Biotechnology Inc1
AbbVie (prior sponsor, Abbott)1
Affiliated Hospital to Academy of Military Medical Sciences1
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1
Bristol-Myers Squibb1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, B-Cell33
Lymphoma, B-Cell19
Leukemia11
Leukemia, Lymphocytic, Chronic, B-Cell9
Lymphoma9
Lymphoma, Mantle-Cell5
Recurrence5
Lymphoma, Follicular4
Lymphoma, Non-Hodgkin4
Precursor Cell Lymphoblastic Leukemia-Lymphoma4

Trials

Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.